FTY720 attenuates tubulointerstitial inflammation and fibrosis in subtotally nephrectomized rats

References

• Eddy AA. Scraping fibrosis: UMODulating renal fibrosis. Nat Med. 2011;17:553–555
   PubMed Web of Science ®Google Scholar
• Hewitson TD. Renal tubulointerstitial fibrosis: common but never simple. Am J Physiol Renal Physiol. 2009;296:F1239–F1244
   PubMed Web of Science ®Google Scholar
• Liu Y, Chowdhury P, Sacks SH, Sheerin NS, Wong W. Pivotal role of CD4+ T cells in renal fibrosis following ureteric obstruction. Kidney Int. 2010;78:351–362
   PubMedGoogle Scholar
• Eardley KS, Zehnder D, Quinkler M, et al. The relationship between albuminuria, MCP-1/CCL2, and interstitial macrophages in chronic kidney disease. Kidney Int. 2006; 69(7):1189–1197
   PubMed Web of Science ®Google Scholar
• López-Hernández FJ, López-Novoa JM. Role of TGF-β in chronic kidney disease: an integration of tubular, glomerular and vascular effects. Cell Tissue Res. 2012;347(1):141–154
   PubMed Web of Science ®Google Scholar
• Cook HT. The origin of renal fibroblasts and progression of kidney disease. Am J Pathol. 2010; 176(1):22–24
   PubMed Web of Science ®Google Scholar
• Hoitsma AJ, Woodle ES, Abramowicz D, Proot P, Vanrenterghem Y. FTY720 combined with tacrolimus in de novo renal transplantation: 1-year, multicenter, open-label randomized study. Nephrol Dial Transplant. 2011;26(11):3802–3805
   PubMedGoogle Scholar
• Matloubian M, Lo CG, Cinamon G, et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature. 2004;427(6972):355–360
   PubMed Web of Science ®Google Scholar
• Peters H, Martini S, Wang Y, et al. Selective lymphocyte inhibition by FTY720 slows the progressive course of chronic anti-thy1 glomerulosclerosis. Kidney Int. 2004;6(4):1434–1443
   Google Scholar
• Awad AS, Ye H, Huang L, et al. Selective sphingosine 1-phosphate 1 receptor activation reduces Ischemia-reperfusion injury in mouse kidney. Am J Physiol Renal Physiol. 2006;290(6):1516–1524
   PubMed Web of Science ®Google Scholar
• Schaier M, Vorwalder S, Sommerer C, et al. Role of FTY720 on M1 and M2 macrophages, lymphocytes, and chemokines in 5/6 nephrectomized rats. Am J Physiol Renal Physiol. 2009;297(3):769–780
   PubMed Web of Science ®Google Scholar
• Krämer S, Binder E, Loof T, et al. The lymphocyte migration inhibitor FTY720 attenuates experimental hypertensive nephropathy. Am J Physiol Renal Physiol. 2009;297(1):F218–F227
   Google Scholar
• Sui M, Zhou J, Xie R, et al. The sphingosine-1-phosphate receptor agonist FTY720 prevents the development of anti-glomerular basement membrane Glomerulonephritis. Mol Biol Rep. 2012;39(1):389–397
   PubMedGoogle Scholar
• Ji L, Masuda S, Saito H, Inui K. Down-regulation of rat organic cation transporter rOCT2 by 5/6 nephrectomy. Kidney Int 2002;62:514–524
   PubMed Web of Science ®Google Scholar
• Finney CA, Hawkes CA, Kain DC, et al. S1P is associated with protection in human and experimental cerebral malarial. Mol Med. 2011;17(7–8):717–725
   PubMedGoogle Scholar
• Chen JF, Ni HF, Pan MM, et al. Pirfenidone inhibits macrophage infiltration in 5/6 nephrectomized rats. Am J Physiol Renal Physiol. 2013;304(6):F676–F685
   PubMed Web of Science ®Google Scholar
• An WS, Kim HJ, Cho KH, Vaziri ND. Omega-3 fatty acid supplementation attenuates oxidative stress, inflammation, and tubulointerstitial fibrosis in the remnant kidney. Am J Physiol Renal Physiol. 2009;297(4):895–903
   PubMed Web of Science ®Google Scholar
• Krämer S, Loof T, Martini S, et al. Mycophenolate mofetil slows progression in anti-thy1-induced chronic renal fibrosis, but is not additive to a high dose of enalapril. Am J Physiol Renal Physiol. 2005;289(2):F359–F368
   Google Scholar
• Anders HJ. Four danger response programs determine glomerular and tubulointerstitial kidney pathology: clotting, inflammation, epithelial and mesenchymal healing. Organogenesis. 2012;8(2):1–12
   PubMedGoogle Scholar
• Boor P, Sebeková K, Ostendorf T, Floege J. Treatment targets in renal fibrosis. Nephrol Dial Transplant. 2007;22(12):3391–3407
   PubMed Web of Science ®Google Scholar
• Zeisberg M, Neilson EG. Mechanisms of tubulointerstitial fibrosis. J Am Soc Nephrol. 2010;21(11):1819–1834
   PubMed Web of Science ®Google Scholar
• Anders HJ, Ryu M. Renal microenvironments and macrophage Phenotypes determine progression or resolution of renal inflammation and fibrosis. Kidney Int. 2011;80(9):915–925
   PubMed Web of Science ®Google Scholar
• Tapmeier TT, Fearn A, Brown K, et al. Pivotal role of CD4+ T cells in renal fibrosis following ureteric obstruction. Kidney Int. 2010;78(4):351–362
   PubMed Web of Science ®Google Scholar
• Husby G, Tung KS, Williams RC Jr. Characterization of renal tissue lymphocytes in patients with interstitial nephritis. Am J Med. 1981;70:31–38
   PubMed Web of Science ®Google Scholar
• Rosen H, Goetzl EJ. Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network. Nat Rev Immunol. 2005;5(7):560–570
   PubMed Web of Science ®Google Scholar
• Singer II, Tian M, Wickham LA, et al. Sphingosine-1-phosphate agonists increase macrophage homing, lymphocyte contacts, and endothelial junctional complex formation in murine lymph nodes. J Immunol. 2005;175(11):7151–7161
   PubMed Web of Science ®Google Scholar
• Eardley KS, Zehnder D, Quinkler M, et al. The relationship between albuminuria, MCP-1/CCL2, and interstitial macrophages in chronic kidney disease. Kidney Int. 2006;9(7):1189–1197
   Google Scholar
• Rovin BH, Lu L, Marsh CB. Lymphocytes induce monocyte chemoattractant protein1 production by renal cells after Fc gamma receptor cross-linking: role of IL-1 beta. J Leukoc Biol. 2001;69(3):435–439
   PubMedGoogle Scholar
• Ricardo SD, Van Goor H, Eddy AA. Macrophage diversity in renal injury and repair. J Clin Invest. 2008;118(11):3522–3530
   PubMed Web of Science ®Google Scholar
• Lin SL, Castaño AP, Nowlin BT, Lupher Jr ML, Duffield JS. Bone marrow Ly6Chigh monocytes are selectively recruited to injured kidney and differentiate into functionally distinct populations. J Immunol. 2009;183(10):6733–6743
   PubMed Web of Science ®Google Scholar
• Badylak SF, Valentin JE, Ravindra AK, McCabe GP, Stewart-Akers AM. Macrophage phenotype as a determinant of biologic scaffold remodeling. Tissue Eng Part A. 2008;14(11):1835–1842
   PubMed Web of Science ®Google Scholar
• Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med. 2006;355(11):1124–1140
   PubMed Web of Science ®Google Scholar
• Pfeilschifter W, Czech-Zechmeister B, Sujak M, Foerch C, Wichelhaus TA, Pfeilschifter J. Treatment with the immunomodulator FTY720 does not promote spontaneous bacterial infections after experimental stroke in mice. Exp Transl Stroke Med. 2011;3:2–7
   PubMedGoogle Scholar
• Johnson TA, Lapierre Y, BarOr A, Antel JP. Distinct properties of circulating CD8+ T cells in FTY720-treated patients with multiple sclerosis. Arch Neurol. 2010;67:1449–1455
   PubMed Web of Science ®Google Scholar